Your browser doesn't support javascript.
loading
Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
Ueki, Yuya; Otsuka, Hideki; Otani, Tamaki; Kasai, Ryosuke; Otomi, Yoichi; Ikemitsu, Daiki; Azane, Shota; Kunikane, Yamato; Bando, Takanori; Matsuda, Noritake; Okada, Yasuyuki; Takayama, Tetsuji; Harada, Masafumi.
Afiliación
  • Ueki Y; Tokushima University Graduate School of Health Sciences, Tokushima, Japan.
  • Otsuka H; Department of Medical Imaging/Nuclear Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. hideki.otsuka@tokushima-u.ac.jp.
  • Otani T; Advance Radiation Research, Education and Management Center, Tokushima University, Tokushima, Japan.
  • Kasai R; Department of Medical Imaging/Nuclear Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Otomi Y; Department of Radiology and Radiation Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Ikemitsu D; Department of Radiology, Tokushima University Hospital, Tokushima, Japan.
  • Azane S; Department of Radiology, Tokushima University Hospital, Tokushima, Japan.
  • Kunikane Y; Department of Radiology, Tokushima University Hospital, Tokushima, Japan.
  • Bando T; Department of Radiology, Tokushima University Hospital, Tokushima, Japan.
  • Matsuda N; Department of Radiology, Tokushima University Hospital, Tokushima, Japan.
  • Okada Y; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Takayama T; Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Harada M; Department of Radiology and Radiation Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Jpn J Radiol ; 42(5): 519-535, 2024 May.
Article en En | MEDLINE | ID: mdl-38345724
ABSTRACT

PURPOSE:

Somatostatin receptor scintigraphy (SRS) using 111In-DTPA-DPhe1-octreotide (pentetreotide) has become an integral part of neuroendocrine neoplasm management. The lack of precise quantification is a disadvantage of SRS. This study aimed to adapt the standardized uptake value (SUV) to SRS, establish the SUV range for physiological uptake in the liver, kidney, and spleen, and elucidate the utility of combined visual and quantitative SRS assessment for staging and restaging of neuroendocrine tumors (NETs). MATERIALS AND

METHODS:

This study included 21 patients with NETs who underwent 111In-pentetreotide SRS. The SUV of physiological and pathological uptake was calculated using bone single-photon emission computed tomography (SPECT) quantitative analysis software (GI-BONE). For visual analysis, the primary and metastatic lesions were scored visually on planar and SPECT images using a five-point scale. We assessed the relationships between the SUVs of the liver, kidney, and spleen in the dual phase, and among quantitative indices, visual score, and pathological lesions classification.

RESULTS:

Sixty-three NEN lesions were evaluated. The mean ± standard deviation maximum SUVs (SUVmax) were liver 4 h, 2.6 ± 1.0; 24 h, 2.2 ± 1.0; kidney 4 h, 8.9 ± 1.8; 24 h, 7.0 ± 2.0; and spleen; 4 h, 11.3 ± 4.5; 24 h, 11.5 ± 7.6. Higher SUVmax was significantly associated with higher visual scores on dual-phase SPECT (4 h, p < 0.001; 24 h, p < 0.001) (4 h scores 3 and 4, p < 0.05; scores 3 and 5 p < 0.01; scores 4 and 5 p < 0.01; 24 h scores 3 and 4, p = 0.0748; scores 3 and 5 p < 0.01; scores 4 and 5 p < 0.01).

CONCLUSION:

We adapted the SUV to SRS and established the range of SUV for physiological uptake in the liver, kidney, and spleen. Combined visual and quantitative assessment is useful for imaging individual lesions in greater detail, and may serve as a new tumor marker of SRS for staging and restaging of NETs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Somatostatina / Receptores de Somatostatina / Tumores Neuroendocrinos / Radiofármacos / Estadificación de Neoplasias Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Jpn J Radiol Asunto de la revista: DIAGNOSTICO POR IMAGEM / RADIOLOGIA / RADIOTERAPIA Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Somatostatina / Receptores de Somatostatina / Tumores Neuroendocrinos / Radiofármacos / Estadificación de Neoplasias Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Jpn J Radiol Asunto de la revista: DIAGNOSTICO POR IMAGEM / RADIOLOGIA / RADIOTERAPIA Año: 2024 Tipo del documento: Article País de afiliación: Japón